AdipoGen Life Sciences


CHF 70.00
In stock
AG-CR1-3602-M0055 mgCHF 70.00
AG-CR1-3602-M02525 mgCHF 280.00
More Information
Product Details
Synonyms PS-341; LDP-341; MLM-341; MG-341; NSC-681239; Proteasome Inhibitor
Product Type Chemical


MW 384.2
CAS 179324-69-7
RTECS ED7771666
Purity Chemicals ≥97% (NMR)
Appearance White solid.
Solubility Soluble in DMSO, ethanol or methanol. Slightly soluble in water.
Smiles CC(C)C[C@H](NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)C1=NC=CN=C1)B(O)O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light.
Use/Stability Stable for at least 1 year after receipt when stored at -20°C.
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Highly potent, selective and reversible cell permeable inhibitor of the proteasome. Inhibits the chymotrypsin-like and caspase-like peptidase activity of the proteasome.
  • Calpain and cathepsin inhibitor.
  • Autophagy activator.
  • Anticancer compound. Inhibits proliferation and migration of several tumor cell lines with nanomolar potency.
  • Apoptosis inducer.
Product References
  1. Proteasome inhibitors: a novel class of potent and effective antitumor agents: J. Adams, et al.; Cancer Res. 59, 2615 (1999)
  2. Development of the proteasome inhibitor Velcade (Bortezomib): J. Adams & M. Kauffmann; Cancer Invest. 22, 304 (2004)
  3. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells: S.T. Nawrocki, et al.; Cancer Res. 65, 11510 (2005)
  4. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib: D. Chauhan, et al.; Cancer Cell 8, 407 (2005)
  5. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate: A.F. Kisselev, et al.; J. Biol. Chem. 281, 8582 (2006)
  6. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro: T.M. Horton, et al.; Cancer Chemother. Pharmacol. 58, 13 (2006)
  7. Bortezomib as an antitumor agent: A.M. Roccaro, et al.; Curr. Pharm. Biotechnol. 7, 441 (2006) (Review)
  8. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib: A. Kardosh, et al.; Cancer Res. 68, 843 (2008)
  9. Proteasome inhibitor PS-341 (bortezomib) induces calpain-dependent IkappaB(alpha) degradation: C. Li, et al.; J. Biol. Chem. 285, 16096 (2010)
  10. Bortezomib suppresses function and survival of plasmacytoid dendritic cells by targeting intracellular trafficking of Toll-like receptors and endoplasmic reticulum homeostasis: M. Hirai, et al.; Blood 117, 500 (2011)
  11. Bortezomib, a proteasome inhibitor, attenuates angiotensin II-induced hypertension and aortic remodeling in rats: S. Li, et al; PLoS One 8, e78564 (2013)
  12. Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells: H. Min, et al.; Cancer Chemother. Pharmacol. 74, 167 (2014)
  13. Bortezomib is a rapid mobilizer of hematopoietic stem cells in mice via modulation of the VCAM-1/VLA-4 axis: A. Ghobadi, et al.; Blood 124, 2752 (2014)
  14. Bortezomib inhibits C2C12 growth by inducing cell cycle arrest and apoptosis: S.S. Xing, et al.; BBRC 445, 375 (2014)
  15. Bortezomib prevents oncogenesis and bone metastasis of prostate cancer by inhibiting WWP1, Smurf1 and Smurf2: Z. Wang, et al.; Int. J. Oncol. 45, 1469 (2014)
  16. Efficient apoptosis and necrosis induction by proteasome inhibitor: bortezomib in the DLD-1 human colon cancer cell line: R. Krętowski, et al.; Mol. Cell Biochem. 398, 165 (2015)
  17. Live cell, image-based high-throughput screen to quantitate p53 stabilization and viability in human papillomavirus positive cancer cells: G. Martinez-Noel, et al.; Virology 560, 96 (2021)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.